28 Results for "

ESCC cells

" in MedChemExpress (MCE) Product Catalog:
Products (28)

28 Results for "ESCC cells" in MCE Product Catalog:

Cat. No.: HY-10261AR
CAS No.: 850140-73-7
Synonyms: BIBW 2992MA2 (Standard)
Afatinib (dimaleate) (Standard) is the analytical standard of Afatinib (dimaleate). This product is intended for research and analytical applications. Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib dimaleate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .
loading...
    loading...
Cat. No.: HY-172878
CAS No.: 3062141-62-9
Research Areas:  

Cancer

HDAC/PSMD14-IN-1 (Compound 8B) is a thiolutin derivative. HDAC/PSMD14-IN-1 is a orally active dual-target inhibitor of PSMD14/HDAC1 (IC50 238.7 nM/141.2 nM, respectively). HDAC/PSMD14-IN-1 has good cytotoxicity against ESCC cell lines (IC50: 30-250 nM) and effectively reverses epithelial-mesenchymal transition (EMT). HDAC/PSMD14-IN-1 can induce apoptosis. HDAC/PSMD14-IN-1 has anti-tumor activity in a KYSE30 cell mouse xenograft model. HDAC/PSMD14-IN-1 can be used in anti-esophageal cancer research .
loading...
    loading...
Cat. No.: HY-180897
CAS No.: 3034203-03-4
Research Areas:  

Cancer

RSK4-IN-2 (compound 16o) is a potent, orally active RSK4 inhibitor with an IC50 of 17 nM. RSK4-IN-2 suppresses esophageal squamous cell carcinoma (ESCC) cell growth and invasion, by inhibiting phosphorylation of RSK4 downstream targets. RSK4-IN-2 inhibits tumor growth and metastasis in ESCC mouse models. RSK4-IN-2 can be used for ESCC research .
loading...
    loading...
Cat. No.: HY-130558
CAS No.: 2000199-44-8
Research Areas:  

Cancer

SL-1-73 is a tubulin ligand. SL-1-73 exhibits antitumor activity against esophageal squamous cell carcinoma (ESCC) both in vitro and in vivo by inhibiting microtubule assembly, inducing G2/M phase cell cycle arrest and apoptosis, and disrupting tumor blood vessels. SL-1-73 can be used for the research of ESCC and other tumors .
loading...
    loading...
Cat. No.: HY-180880
CAS No.: 668435-69-6
Target:  

Apoptosis

Research Areas:  

Cancer

TFAP2β modulator-1 (compound A6) is a potent TFAP2β modulator that promotes TFAP2β condensation by inducing conformational changes in the intrinsically disordered region. TFAP2β modulator-1 promotes TFAP2β condensation, induces apoptosis, and exhibits anti-tumor functions in esophageal squamous cell carcinoma (ESCC) cells, mouse models, and organoids. TFAP2β modulator-1 can be used for ESCC research .
loading...
    loading...
Cat. No.: HY-178825B
Research Areas:  

Cancer

LD-110 trihydrochloride is a PROTAC degrader targeting LSD1 with a DC50 of 0.44-1.24 μM. LD-110 trihydrochloride acts through the CRBN E3 ubiquitin ligase and the ubiquitin-proteasome system, leading to H3K4me2 accumulation. LD-110 trihydrochloride induces apoptosis and inhibits the growth and survival of multiple esophageal squamous cell carcinoma (ESCC) cell lines. LD-110 trihydrochloride inhibits tumor growth in the KYSE-150 xenograft model. LD-110 trihydrochloride can be used in research related to esophageal squamous cell carcinoma .
loading...
    loading...
Cat. No.: HY-178825A
Research Areas:  

Cancer

LD-110 triTFA is a PROTAC degrader targeting LSD1 with a DC50 of 0.44-1.24 μM. LD-110 triTFA acts through the CRBN E3 ubiquitin ligase and the ubiquitin-proteasome system, leading to H3K4me2 accumulation. LD-110 triTFA induces apoptosis and inhibits the growth and survival of multiple esophageal squamous cell carcinoma (ESCC) cell lines. LD-110 triTFA inhibits tumor growth in the KYSE-150 xenograft model. LD-110 triTFA can be used in research related to esophageal squamous cell carcinoma .
loading...
    loading...
Cat. No.: HY-184535
CAS No.: 3008320-14-4
PDIC-DPC is a HMGA1 inhibitor and lung-targeting agent. PDIC-DPC upregulates STING expression and enhances STING-mediated immune signaling. PDIC-DPC inhibits the TGFβ-Smad pathway and activates AMPK. PDIC-DPC forms nanocomplexes with fibrinogen β chain and vitronectin, and achieves lung-specific accumulation by binding to pulmonary endothelial receptors. PDIC-DPC reverses established pulmonary fibrosis, reduces collagen deposition, restores alveolar structure, improves pulmonary function, and inhibits in situ ESCC growth. PDIC-DPC can be used for the research of esophageal squamous cell carcinoma and idiopathic pulmonary fibrosis .
loading...
    loading...